COPENHAGEN – The investments are key links in Sunstone Capital’s strategy to help strengthen growth potential for established biotech firms in the Oresund Region. Sunstone has done this by contributing its own money as well as by raising capital from local and international investors.
NsGene A/S announced today that its Clinical Trial Application (CTA) to start a phase Ib study of NsG0202 for Alzheimer’s disease (AD) has been approved by the Swedish Medical Products Agency (MPA).
Danish biotech company Egalet strengthens management by appointing internationally experienced CFO
Danish specialty pharmaceutical company Egalet has appointed Mr Bertrand Damour as its Chief Financial Officer and Executive Vice President.
Mr Damour has extensive experience in the international financial markets and biotechnology industry and will reinforce Egalet’s position in the global pharmaceutical and biotechnology sector.
Novel Natural History Study to answer question in Rare Disease
The Natural History Study of the rare lysosomal disease alpha-Mannosidosis will answer the question; why the rare disease develops as it does? The first patients have been included in the first Natural History Study of the disease, being conducted under the HUE-MAN project, a 6th framework, EU grant supported initiative.
Santaris Pharma consortium awarded €1.35m by Denmark’s Advanced Technology Foundation for development of the first microRNA medicine
Santaris Pharma announced today that the Danish National Advanced Technology Foundation (ATF) has awarded a grant of €1.35 million towards the development of the first ever drug targeted against a human microRNA.
The drug candidate, SPC3649, is an antagonist of the liver-specific microRNA-122 and is being developed by Santaris in collaboration with the Centre for Biological Sequence Analyses at the Technical University of Denmark and the Department of Cellular and Molecular Medicine, University of Copenhagen.